Why do we need treatment options in multiple myeloma?

  • In every new line of therapy, approximately 50% of patients die, or are lost to follow-up2
  • As the disease progresses and becomes resistant to treatment, there are fewer treatment options resulting in poor outcomes for triple class refractory patients, who have less than 12 months overall survival.3,4
  • BCMA is expressed in 100% of multiple myeloma patients, making it an ideal target5,6


BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1

The DREAMM-2 clinical trial studied BLENREP as a single agent in triple-class refractory patients with multiple myeloma (n=97; 40-month follow up analysis)*7,8

*Median seven prior lines of therapy in DREAMM-2 patient population. BLENREP is indicated for patients who have received at least four prior lines of therapy.1,8

BLENREP must be reconstituted and diluted by a healthcare professional prior to administration as an intravenous infusion. 2.5 mg/kg IV administration, until disease progression or unacceptable toxicity.1

DREAMM-2 clinical trial

Learn more about the pivotal DREAMM-2 clinical trial for BLENREP

Explore our range of BLENREP content


Responses to BLENREP were deep, durable and fast in a heavily pre-treated triple-class refractory population1,8

  • 32% response rate (n=31/97; 97.5% confidence interval (CI): 21.7-43.6) for patients who have received a median of seven prior lines of therapy - 58% (n=18/31) of patients whose disease responded achieved a very good partial response (VGPR) or better response8


BLENREP has a generally well tolerate and manageable safety profile1

  • Side effects were generally manageable through dose delays and modifications in some patients, with no requirement for steroids as premedication1
  • In line with the SmPC, some patients may need to discontinue treatment for severe adverse events.1 12% of patients (n=11/95) discontinued BLENREP due to adverse events.8


BLENREP offers a treatment option for a broad range of patients who need BCMA-targeted in the 5th line setting, and who are triple-class refractory1

  • Outpatient administration, with an intravenous infusion over a minimum of 30 minutes, once every 3 weeks1
  • No steroids, like dexamethasone, are required prior to starting treatment with BLENREP1


Please refer to the SmPC for a full list of adverse events and for the dosing schedule.

Prescribing information can be found at the top of this webpage, or here.


BCMA, B-cell maturation antigen; CI, confidence interval; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; MoA, mechanism of action; NR, not reached; RRMM, relapsed/refractory multiple myeloma; VGPR, very good partial response.


  1. BLENREP Summary of Product Characteristics.
  2. Fonseca R, et al. Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma. Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition; December 1–4, 2018; San Diego, California. Abstract #3291.
  3. Mikhael J. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
  4. Gandhi UH et al. Leukemia. 2019;33:2266-2275.
  5. Tai YT, Anderson KC. Immunotherapy. 2015;7(11):1187–1199.
  6. Farooq AV, et al. Ophthalmol Ther. 2020;9(4):889–911.
  7. Lonial S, et al. Cancer. 2021;127(22):4198–4212.
  8. Ramasamy, K et al. Poster presented at the British Society of Haematology (BSH) on the 63rd Annual Scientific Meeting, 23-25 April 2023, ICC in Birmingham.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or email us on UKSafety@gsk.com.

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

February 2024 | PM-GB-BLM-WCNT-220010 (V5.0)